Default company panoramic image


NirvaMed is developing a new technology to prevent 80% of tissue damage resulting from the current heart attack treatments.

  • Stage Concept Only
  • Industry Medical Devices and Equipment
  • Location St Paul, MN, USA
  • Currency USD
  • Employees 1
  • Website

Company Summary

Setting a new standard of heart attack treatment, NirvaMed is introducing a novel patent-pending technology that prevents tissue inflammation caused by sudden return of blood flow after opening the blocked artery, and improves oxygen supply and microcirculation blood flow to the damaged heart muscle. These are unsolved problems of the current heart attack treatment that cause heart failure in 1 of 4 and kill 1 of 10 massive heart attack patients.


  • Default avatar
    Pramote Hochareon
    Founder & CEO

    Before founding NirvaMed, Pramote was a senior scientist at Boston Scientific, leading several critical concept & product development projects, e.g. arrhythmia detection and heart failure monitoring technologies. With his leadership, NirvaMed was recognized as the finalist of Minnesota and Wisconsin business plan contests. Pramote received M.D. and Ph.D. in Bioengineering in The Artificial Heart. He also won international research grants.

  • Default avatar
    Ed Shapland
    business advisor

    NirvaMed’s primary business advisor is Ed Shapland. Among his successful track record from CPI to several startups, most recently, he cofounded Osprey Medical, a medical device company developing minimally-invasive heart catheter to remove contrast media used during coronary intervention to prevent kidney failure. He has also served in a board of directors for several medical device companies. Ed received his Ph.D. in Physiology.


  • Default avatar
    Kevin Spreng
    Default avatar
    Mike Bromelkamp